Mersana Therapeutics to Host Second Quarter 2024 Conference Call on August 13, 2024
Mersana Therapeutics (NASDAQ: MRSN), a clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) for cancer treatment, has announced its upcoming second quarter 2024 financial results and business update conference call. The event is scheduled for Tuesday, August 13, 2024, at 8:00 a.m. Eastern Time. Investors and interested parties can access the call via phone or webcast. The webcast will be available on the company's website for approximately 90 days following the conference call.
Mersana Therapeutics (NASDAQ: MRSN), un'azienda biofarmaceutica in fase clinica che sviluppa coniugati farmaco-anticorpo (ADCs) per il trattamento del cancro, ha annunciato la sua prossima chiamata per i risultati finanziari del secondo trimestre 2024 e aggiornamenti aziendali. L'evento è programmato per martedì 13 agosto 2024, alle 8:00 ora orientale. Gli investitori e le parti interessate possono partecipare alla chiamata tramite telefono o webcast. Il webcast sarà disponibile sul sito web dell'azienda per circa 90 giorni dopo la chiamata di conferenza.
Mersana Therapeutics (NASDAQ: MRSN), una compañía biofarmacéutica en etapa clínica que desarrolla conjugados anticuerpo-fármaco (ADCs) para el tratamiento del cáncer, ha anunciado su próxima conferencia telefónica sobre los resultados financieros del segundo trimestre de 2024 y actualizaciones comerciales. El evento está programado para el martes 13 de agosto de 2024, a las 8:00 a.m. hora del Este. Los inversores y partes interesadas pueden acceder a la llamada por teléfono o transmisión web. La transmisión estará disponible en el sitio web de la compañía durante aproximadamente 90 días después de la conferencia.
머산아 치료제 (NASDAQ: MRSN)는 암 치료를 위한 항체-약물 접합체 (ADCs)를 개발하고 있는 임상 단계의 바이오 제약 회사로, 2024년 2분기 재무 결과 및 비즈니스 업데이트 컨퍼런스 콜을 발표했습니다. 이 행사는 2024년 8월 13일 화요일, 동부 표준시 오전 8시로 예정되어 있습니다. 투자자 및 관심 있는 분들은 전화 또는 웹캐스트를 통해 콜에 참여할 수 있습니다. 웹캐스트는 컨퍼런스 콜 이후 약 90일 동안 회사 웹사이트에서 제공됩니다.
Mersana Therapeutics (NASDAQ: MRSN), une entreprise biopharmaceutique en phase clinique développant des conjugués anticorps-médicaments (ADCs) pour le traitement du cancer, a annoncé sa prochaine conférence téléphonique sur les résultats financiers du deuxième trimestre 2024 et les mises à jour commerciales. L'événement est prévu pour le mardi 13 août 2024, à 8h00, heure de l'Est. Les investisseurs et les parties intéressées peuvent accéder à l'appel par téléphone ou par webinaire. Le webinaire sera disponible sur le site de l'entreprise pendant environ 90 jours après la conférence.
Mersana Therapeutics (NASDAQ: MRSN), ein biopharmazeutisches Unternehmen in der klinischen Phase, das Antikörper-Wirkstoff-Konjugate (ADCs) zur Krebsbehandlung entwickelt, hat seine bevorstehende Konferenzschaltung zu den Finanzzahlen des zweiten Quartals 2024 und Unternehmensupdates angekündigt. Die Veranstaltung ist für Dienstag, den 13. August 2024, um 8:00 Uhr Eastern Time geplant. Investoren und interessierte Parteien können die Schaltung per Telefon oder Webcast verfolgen. Der Webcast wird auf der Unternehmenswebsite etwa 90 Tage nach der Konferenz verfügbar sein.
- None.
- None.
CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the second quarter ended June 30, 2024 on Tuesday, August 13, 2024. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.
To access the call, please dial 833-255-2826 (domestic) or 412-317-0689 (international). A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com, and a replay of the webcast will be available in the same location following the conference call for approximately 90 days.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Mersana routinely posts information that may be useful to investors on the “Investors & Media” section of its website at www.mersana.com.
Contact:
Jason Fredette
617-498-0020
jason.fredette@mersana.com
FAQ
When will Mersana Therapeutics (MRSN) report its Q2 2024 earnings?
What time is Mersana Therapeutics' (MRSN) Q2 2024 earnings call?
How can I access Mersana Therapeutics' (MRSN) Q2 2024 earnings call?
Where can I find the replay of Mersana Therapeutics' (MRSN) Q2 2024 earnings call?
